Literature DB >> 30755425

'When you hear hooves, think zebras, not horses'; two challenging cases of interstitial lung disease (ILD).

Marissa O'Callaghan1,2, Aurelie Fabre2,3, Michael Keane1,2, Timothy J McDonnell1.   

Abstract

Our case series describes two siblings with complex fibrosing lung diseases. The first patient was initially given a diagnosis of sarcoidosis based on imaging and exclusion of alternative diagnoses. A number of years after diagnosis, he had rapid deterioration of his disease and following surgical lung biopsy, his lung fibrosis was re-classified as chronic hypersensitivity pneumonitis (cHP) with a usual interstitial pneumonia pattern. He subsequently underwent successful lung transplantation. The second patient presented with rapidly progressing exertional dyspnoea. His bloods, imaging, bronchoalveolar lavage and histology were discussed at our multidisciplinary team meeting. His histology was most in keeping with subacute on cHP with overlapping imaging features between the two siblings. He was treated accordingly but unfortunately succumbed to his illness shortly after diagnosis. These cases highlight the difficulties differentiating between the various interstitial lung disease (ILD) subtypes and the challenges in management while also increasing awareness of familial ILD. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiothoracic surgery; drugs: respiratory system; interstitial lung disease; medical management; respiratory medicine

Mesh:

Year:  2019        PMID: 30755425      PMCID: PMC6381985          DOI: 10.1136/bcr-2018-224507

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment.

Authors:  Harpreet K Lota; Gregory J Keir; David M Hansell; Andrew G Nicholson; Toby M Maher; Athol U Wells; Elisabetta A Renzoni
Journal:  Thorax       Date:  2013-03-20       Impact factor: 9.139

2.  Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey.

Authors:  Julie Morisset; Kerri A Johannson; Kirk D Jones; Paul J Wolters; Harold R Collard; Simon L F Walsh; Brett Ley
Journal:  Am J Respir Crit Care Med       Date:  2017-11-27       Impact factor: 21.405

3.  [Case Report; A case of parents and child who simultaneously suffered from summer-type hypersensitivity pneumonitis].

Authors:  Hiroyuki Kokuto; Shuichi Matsuda; Shingo Tsuji; Takeshi Osawa; Kazunari Yamana; Takashi Uchiyama; Yuka Sasaki; Mikio Saotome; Hideo Ogata; Hajime Goto
Journal:  Nihon Naika Gakkai Zasshi       Date:  2016-03-10

4.  Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.

Authors:  Julie Morisset; Kerri A Johannson; Eric Vittinghoff; Carlos Aravena; Brett M Elicker; Kirk D Jones; Charlene D Fell; Helene Manganas; Bruno-Pierre Dubé; Paul J Wolters; Harold R Collard; Christopher J Ryerson; Brett Ley
Journal:  Chest       Date:  2016-11-03       Impact factor: 9.410

5.  A familial history of pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis.

Authors:  Tsukasa Okamoto; Yasunari Miyazaki; Makoto Tomita; Meiyo Tamaoka; Naohiko Inase
Journal:  Respiration       Date:  2012-06-09       Impact factor: 3.580

Review 6.  Chronic hypersensitivity pneumonitis and pulmonary sarcoidosis: differentiation from usual interstitial pneumonia using high-resolution computed tomography.

Authors:  Yeon Joo Jeong; Kyung Soo Lee; Man Pyo Chung; Joungho Han; Takeshi Johkoh; Kazuya Ichikado
Journal:  Semin Ultrasound CT MR       Date:  2013-10-17       Impact factor: 1.875

Review 7.  Inherited interstitial lung disease.

Authors:  Christine Kim Garcia; Ganesh Raghu
Journal:  Clin Chest Med       Date:  2004-09       Impact factor: 2.878

8.  Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study.

Authors:  Simon L F Walsh; Athol U Wells; Sujal R Desai; Venerino Poletti; Sara Piciucchi; Alessandra Dubini; Hilario Nunes; Dominique Valeyre; Pierre Y Brillet; Marianne Kambouchner; António Morais; José M Pereira; Conceição Souto Moura; Jan C Grutters; Daniel A van den Heuvel; Hendrik W van Es; Matthijs F van Oosterhout; Cornelis A Seldenrijk; Elisabeth Bendstrup; Finn Rasmussen; Line B Madsen; Bibek Gooptu; Sabine Pomplun; Hiroyuki Taniguchi; Junya Fukuoka; Takeshi Johkoh; Andrew G Nicholson; Charlie Sayer; Lilian Edmunds; Joseph Jacob; Maria A Kokosi; Jeffrey L Myers; Kevin R Flaherty; David M Hansell
Journal:  Lancet Respir Med       Date:  2016-05-11       Impact factor: 30.700

9.  Familial hypersensitivity pneumonitis induced by Bacillus subtilis.

Authors:  C L Johnson; I L Bernstein; J S Gallagher; P F Bonventre; S M Brooks
Journal:  Am Rev Respir Dis       Date:  1980-08

10.  Rituximab in severe, treatment-refractory interstitial lung disease.

Authors:  Gregory J Keir; Toby M Maher; Damien Ming; Reza Abdullah; Angelo de Lauretis; M Wickremasinghe; Andrew G Nicholson; David M Hansell; Athol U Wells; Elisabetta A Renzoni
Journal:  Respirology       Date:  2013-11-29       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.